Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Lignende værker

• Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
  af: Heerspink, H. J. L., et al.
  Udgivet: (2016)
• Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
  af: Heerspink, Hiddo J. L., et al.
  Udgivet: (2018)
• Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
  af: Fioretto, Paola, et al.
  Udgivet: (2016)
• Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
  af: Kohan, Donald E, et al.
  Udgivet: (2014)
• Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
  af: Dekkers, Claire C J, et al.
  Udgivet: (2018)